Celldex Therapeutics

CLDX · Nasdaq · United States

Share price · CLDX

$27.55-14.24 (-34.08%) 3M

close as of 2026-11-18 · 24h delayed · vol 680K (0.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when CLDX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 22 Sep 2026-11.6%
  2. 14 Sep 2026+6.2%

    Nothing announced by CLDX that day or the session before.

  3. 5 Aug 2026+5.1%

    Nothing announced by CLDX that day or the session before.

  4. 29 Jul 2026+5.4%
  5. 16 Jul 2026-7.6%
  6. 7 Jul 2026+5.2%

    Nothing announced by CLDX that day or the session before.

  7. 29 Jun 2026+6.2%
  8. 12 Jun 2026+4.4%

    Nothing announced by CLDX that day or the session before.

  9. 25 Feb 2026+24.1%
  10. 12 Jan 2026-6.2%

Share of unusual movement by asset

For each asset, the share of CLDX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
barzolvolimab
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—8%
Other company news (earnings, financing, releases naming no asset)—18%
Sessions with no dated event—74%

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
4Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
KITMonoclonal antibody
Atopic DermatitisChronic Spontaneous UrticariaUrticaria
Chronic Inducible Urticaria
Phase 1
TSLP + SCF/KITMultispecific antibody
Asthma

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (2)
June 2028 (1)
barzolvolimabPhase 3Chronic Inducible Urticaria, Cold Urticaria, Cold-Induced Urticaria, Symptomatic Dermographism
Est. primary completion 2028-06 · NCT07266402 · CT.gov ↗
What to watch
September 2028 (1)
barzolvolimabPhase 3Chronic Spontaneous Urticaria
Est. primary completion 2028-09 · NCT07256392 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

22 September 2026Topline resultbarzolvolimabBarzolvolimab Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 topline: primary and all key secondary endpoints met
Celldex Therapeutics · Source ↗
July 2026Topline resultbarzolvolimabPhase 2 in prurigo nodularis did not meet its primary or key secondary endpoints

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$67M$27M+ $623M short-term inv.$76M-$65M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2<$0.1M$68M$47M+ $670M short-term inv.$74M-$57M operating cash flowreport ↗
2026-Q1<$0.1M$73M$452M$79Mreport ↗
2025-Q3—$63M$36M+ $547M short-term inv.$67M-$49M operating cash flowreport ↗
2025-Q2$0.7M$54M$23M+ $607M short-term inv.$57M-$44M operating cash flowreport ↗
2025-Q1$0.7M$53M$17M+ $656M short-term inv.$54M-$54M operating cash flowreport ↗
2024-Q3$3.2M$45M$36M+ $720M short-term inv.$42M-$55M operating cash flowreport ↗
2024-Q2$2.5M$40M$43M+ $760M short-term inv.$36M-$29M operating cash flowreport ↗
2024-Q1$0.2M$32M$115M+ $709M short-term inv.$33M-$41M operating cash flowreport ↗
2023-Q3$1.5M$35M$21M+ $214M short-term inv.—-$19M operating cash flowreport ↗
2023-Q2$0.3M$26M$28M+ $224M short-term inv.—-$27M operating cash flowreport ↗
2023-Q1$1.0M$27M$54M+ $224M short-term inv.—-$29M operating cash flowreport ↗
2022-Q3$0.4M$22M$19M+ $305M short-term inv.—-$35M operating cash flowreport ↗
2022-Q2$0.2M$21M$28M+ $328M short-term inv.—-$22M operating cash flowreport ↗
2022-Q1$0.2M$17M$25M+ $355M short-term inv.—-$25M operating cash flowreport ↗
2021-Q3$0.1M$14M$72M+ $351M short-term inv.—-$16M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$1.6M$245M$29M+ $490M short-term inv.$65M-$211M operating cash flowreport ↗

For fiscal year 2025, Celldex reported revenue of $1.55M, down 77.9% YoY, with R&D spend of $245.07M, up 49.8% YoY. Cash and equivalents stood at $28.87M, and the company reported a net loss of $258.76M with quarterly net burn of $258.76M.

Celldex advanced its clinical pipeline during the period. The Phase 3 CSU program for barzolvolimab completed enrollment in February 2026 with topline data expected in Q4 2026, a Phase 3 study in cold urticaria and symptomatic dermographism was initiated in December 2025, and Phase 2 studies in prurigo nodularis and atopic dermatitis completed enrollment with topline data expected in summer 2026 and late 2026, respectively. The CDX-622 Phase 1a study completed enrollment, with multiple ascending dose and subcutaneous data anticipated in Q3 2026, and a Phase 1 proof-of-mechanism study in mild to moderate asthma was initiated in January 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$7.0M$164M$28M+ $697M short-term inv.$39M-$158M operating cash flowreport ↗
2023-FY$6.9M$118M$35M+ $389M short-term inv.$35M-$107M operating cash flowreport ↗
2022-FY$2.4M$82M$29M+ $276M short-term inv.$28M-$104M operating cash flowreport ↗
2021-FY$4.7M$53M$39M+ $369M short-term inv.$18M-$61M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 1 sale ($121K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-06-25PENNER HARRY JR · directorAward / grant (derivative)26,000——Form 4
2026-06-25CONRAD HERBERT J · directorAward / grant (derivative)26,000——Form 4
2026-06-25MARINO JAMES J · directorAward / grant (derivative)26,000——Form 4
2026-06-25Brownlie Keith L · directorAward / grant (derivative)26,000——Form 4
2026-06-25Cohen Cheryl · directorAward / grant (derivative)26,000——Form 4
2026-06-25NEIL GARRY ARTHUR · directorAward / grant (derivative)26,000——Form 4
2026-06-25Jain Rita · directorAward / grant (derivative)26,000——Form 4
2026-06-25Torres Denice · directorAward / grant (derivative)26,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 228 reporting institutions held 72.8M shares ($2.2B, 92.7% of shares outstanding).

#InstitutionSharesValue
1WELLINGTON MANAGEMENT GROUP LLP8,560,476$271.5M
2Kynam Capital Management, LP5,840,567$185.3M
3BlackRock, Inc.5,369,885$170.3M
4FMR LLC3,749,048$118.9M
5Point72 Asset Management, L.P.3,229,939$102.5M
6VANGUARD CAPITAL MANAGEMENT LLC2,960,895$93.9M
7STATE STREET CORP2,804,168$88.9M
8Commodore Capital LP2,696,616$85.5M
9Eversept Partners, LP1,788,016$56.7M
10GEODE CAPITAL MANAGEMENT, LLC1,688,074$53.6M
11BRAIDWELL LP1,356,082$43.0M
12Deep Track Capital, LP1,283,979$40.7M
13MILLENNIUM MANAGEMENT LLC1,253,532$39.8M
14Vestal Point Capital, LP1,224,165$38.8M
15NOVO HOLDINGS A/S1,200,000$38.1M